SNN0029 infusion solution ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	2

2. Amyotrophic lateral sclerosis

---

Clinical trials : 645 /  Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02269436 (ClinicalTrials.gov)	January 2015	8/10/2014	A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS	A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: sNN0029 infusion solution	Newron Sweden AB	NULL	Terminated	18 Years	75 Years	Both	11	Phase 1	Belgium;Netherlands
2	NCT01999803 (ClinicalTrials.gov)	September 2014	22/11/2013	A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS	A Phase I, Randomised, Double-blind, Placebo-controlled Study in Patients With Amyotrophic Lateral Sclerosis to Further Assess the Safety and Tolerability of Intracerebroventricular Administration of sNN0029 Infusion Solution	Amyotrophic Lateral Sclerosis	Drug: sNN0029;Drug: Placebo	Newron Sweden AB	NULL	Terminated	18 Years	75 Years	Both	15	Phase 1	Belgium;Netherlands